Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.39 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16086367 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Hydrochloric Acid SCHEMBL1373160 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Hydrochloric Acid SCHEMBL2266284 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL140867 | 0.97 | — | — | |
| SCHEMBL140866 | 0.97 | — | — | |
| SCHEMBL1764859 | 0.97 | — | — | |
| Acetic Acid SCHEMBL11308256 | 0.94 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Methane SCHEMBL5081883 | 0.94 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL8926665 | 0.94 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL28475099 | 0.94 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238615-B2 | Process for the iodination of aromatic compounds | BRACCO IMAGING S.P.A. (IT) | 2016-01-19 | — | — | US | claimed |
| US-20140186272-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2014-07-03 | — | — | US | claimed |
| EP-2421819-B1 | PROCESS FOR THE IODINATION OF AROMATIC COMPOUNDS | BRACCO IMAGING SPA (IT) | 2014-03-05 | — | — | EP | claimed |
| US-8624061-B2 | Process for the preparation of iodinated contrast agent | BRACCO IMAGING S.P.A. (IT) | 2014-01-07 | — | — | US | claimed |
| US-20130216486-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2013-08-22 | — | — | US | claimed |
| US-20120041224-A1 | Process For The Iodination Of Aromatic Compounds | BRACCO IMAGING S.P.A. (IT) | 2012-02-16 | — | — | US | claimed |
| EP-2318356-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | The Procter & Gamble Company (US) | 2011-05-11 | — | — | EP | claimed |
| US-20100076080-A1 | Synthesis of Cyclohexane Derivatives Useful as Sensates in Consumer Products | THE PROCTER & GAMBLE COMPANY | 2010-03-25 | — | — | US | claimed |
| WO-2010019730-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2010-02-18 | — | — | WO | claimed |
| EP-0851854-B1 | PROCESS FOR THE PURIFICATION OF AN INTERMEDIATE IN THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2001-12-12 | — | — | EP | claimed |
| US-5849953-A | Process for the purification of an intermediate | FRUCTAMINE S.P.A. (IT) | 1998-12-15 | — | — | US | claimed |
| EP-0851854-A2 | PROCESS FOR THE PURIFICATION OF AN INTERMEDIATE IN THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING S.p.A. (IT) | 1998-07-08 | — | — | EP | claimed |
| WO-1997047590-A2 | PROCESS FOR THE PURIFICATION OF AN INTERMEDIATE IN THE PREPARATION OF IOPAMIDOL | FRUCTAMINE S.P.A. (IT) | 1997-12-18 | — | — | WO | claimed |
| US-5672735-A | 5-((ACETYLOXY)-1-OXOPROPYL)AMINO)-2,4,6-TRIIODO-1,3-BENZENEDI CARBONYL CHLORIDE BY REACTING 5-AMINO-2,4,6-TRIIODOBENZENE DICARBONYL CHLORIDE WITH THE PROPIONYL CHLORIDE COMPOUND USING AN APROTIC DIPOLAR SOLVENT AND HALOHYDRIC ACID CATALYST | FRUCTAMINE S.P.A. (IT) | 1997-09-30 | — | — | US | claimed |
| US-5580993-A | Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.P.A. (IT) | 1996-12-03 | — | — | US | claimed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024128305-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | 第一三共株式会社 | 2024-06-20 | — | — | WO | disclosed |
| EP-0782565-A1 | IODINATED X-RAY-CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009285-A1 | IODINATED X-RAY-CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1996-03-28 | — | — | WO | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186272-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | NISCH, TRPM4, TRPM8 | CHRM2 730/4885CHRM4 205/4885CHRM1 438/4885 |
| US-20120041224-A1 | Process For The Iodination Of Aromatic Compounds | NISCH, TPO, AOC3 | CHRM2 701/4885CHRM4 542/4885CHRM1 573/4885 |
| US-20100076080-A1 | Synthesis of Cyclohexane Derivatives Useful as Sensates in Consumer Products | NISCH, TRPM4, TRPM8 | CHRM2 730/4885CHRM4 205/4885CHRM1 438/4885 |
| US-20130216486-A1 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | NISCH, TRPM4, TRPM8 | CHRM2 730/4885CHRM4 205/4885CHRM1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.